Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Merck continues to pursue peptidomimetic farnesyltransferase inhibitors

Dec. 30, 1997

VRCTC-310: MTD, preliminary efficacy and pharmacokinetic data in humans

Dec. 29, 1997

SAR leading to new topoisomerase I inhibitor presented by Banyu

Dec. 29, 1997

Peptidomimetic protein farnesyltransferase inhibitors in development at Merck

Dec. 24, 1997

ICI-182780 associated with longer remission duration than megestrol in resistant breast cancer

Dec. 22, 1997

Peptidomimetic inhibitors of protein farnesyltransferase from Merck & Co.

Dec. 22, 1997

Squalamine enters phase I for the treatment of cancer

Dec. 22, 1997

FDA Advisory Committee does not recommend approval for DepoCyt

Dec. 19, 1997

Farnesyltransferase inhibitors lacking a thiol moiety from Merck & Co.

Dec. 19, 1997

More on protein farnesyltransferase inhibitors from Merck & Co.

Dec. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...